1. Academic Validation
  2. Periplocymarin protects against myocardial fibrosis induced by β-adrenergic activation in mice

Periplocymarin protects against myocardial fibrosis induced by β-adrenergic activation in mice

  • Biomed Pharmacother. 2021 Jul;139:111562. doi: 10.1016/j.biopha.2021.111562.
Weijing Yun 1 Lei Qian 1 Ruqiang Yuan 2 Hu Xu 3
Affiliations

Affiliations

  • 1 Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116044, China.
  • 2 Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116044, China. Electronic address: yuanrq666@163.com.
  • 3 Advanced Institute for Medical Sciences, Dalian Medical University, Dalian 116044, China. Electronic address: xuhu1024@126.com.
Abstract

Periplocymarin is an effective component of Periplocae Cortex, which was wildly used as an ingredient in Traditional Chinese Medicine. Our group previously reported that periplocymarin exerted cardiotonic role via promoting calcium influx. However, its exact role in the pathogenesis of myocardial fibrosis has not been elucidated yet. The present study was aimed at determining the potential effect and underlying mechanism of periplocymarin in isoproterenol (ISO)-induced myocardial fibrosis. C57BL/6 mice were subcutaneously injected with ISO (5 mg/kg/day) or saline for 1 week. The early-to-atrial wave ratio (E/A ratio) measured by echocardiography revealed that ISO-induced heart stiffness was remarkably reversed by administration of periplocymarin (5 mg/kg/day). Masson trichrome staining exhibited that treatment of periplocymarin reduced the excessive deposition of extracellular matrix (ECM). Further investigations employing Real-Time PCR and western blot demonstrated that periplocymarin suppressed the expression of fibrosis related genes (Col1a1, Col3a1, Acta2 and Tgfb1) and proteins (Collagen I, Collagen III, α-SMA and TGF-β1) induced by ISO. Metabolomics analysis demonstrated that periplocymarin ameliorated the disorders triggered by ISO and many of the differential metabolic substances were involved in amino acid, glucose and lipid metabolism. Further analysis using network pharmacology revealed that three key genes, namely NOS2, NOS3 and Ptgs2, may be the potential targets of periplocymarin and responsible for the disorders. Validation using heart tissues showed that the mRNA expression of NOS3 was decreased while Ptgs2 was increased upon ISO treatment, which were reversed by periplocymarin. Moreover, the expression of COX-2 (Ptgs2 encoded protein) was consistent with the aspect of Ptgs2 mRNA, while eNOS (NOS3 encoded protein) expression was unchanged. In vitro studies exhibited that periplocymarin exerts anti-fibrotic function via regulating at least eNOS and COX-2 in cardiomyocyte. Taken together, periplocymarin protects against myocardial fibrosis induced by β-adrenergic activation, the potential mechanism was that periplocymarin targeted on, at least eNOS and COX-2, to improve the metabolic processes of cardiomyocyte and thus attenuated the myocardial fibrosis. Our study highlighted that periplocymarin is a potential therapeutic agent for the prevention of myocardial fibrosis.

Keywords

Metabolomics; Myocardial fibrosis; NOS3; Network pharmacology; Periplocymarin; Ptgs2.

Figures
Products